Maintenance therapy in colon cancer.

Area of Science:

• Oncology
• Medical Oncology
• Gastrointestinal Oncology

Background:

• Metastatic colorectal cancer (mCRC) treatment has significantly improved over the last decade.
• New agents like Irinotecan, Oxaliplatin, Bevacizumab, and Cetuximab have enhanced response rates (50-60%) and survival (PFS 9-11 months, OS 20-24 months).
• Despite progress, optimal treatment duration and the role of maintenance therapy remain key unresolved issues.

Purpose of the Study:

• To critically evaluate different treatment strategies for metastatic colorectal cancer.
• To compare alternative approaches against the conventional 'treatment until progression' method.
• To discuss the implications of induction, cessation, and maintenance therapy in mCRC management.

Main Methods:

• Review of current clinical practices and literature on mCRC treatment.
• Analysis of treatment strategies including induction therapy, treatment cessation, and maintenance therapy.
• Comparison of outcomes associated with various therapeutic approaches versus continuous treatment.

Main Results:

• The classical approach involves treatment until disease progression or toxicity.
• Common alternative strategies include induction therapy followed by cessation or maintenance therapy with reduced toxicity.
• The report focuses on analyzing the efficacy and role of these varied strategies.

Conclusions:

• Optimal treatment duration and the value of maintenance therapy in mCRC require further investigation.
• Alternative strategies to continuous treatment may offer benefits regarding toxicity and patient management.
• Further research is needed to define the best therapeutic sequence for metastatic colorectal cancer patients.